Mizuho Reiterates “Buy” Rating for Aerie Pharmaceuticals (NASDAQ:AERI)

Mizuho reissued their buy rating on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a research report released on Tuesday, December 19th. Mizuho currently has a $87.00 price target on the stock.

Several other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a buy rating to a hold rating in a report on Monday, August 28th. Needham & Company LLC reissued a buy rating and issued a $65.00 price target on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Canaccord Genuity reissued a buy rating on shares of Aerie Pharmaceuticals in a research report on Friday, September 22nd. Cowen reaffirmed a buy rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $62.00 price objective on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $72.00.

Aerie Pharmaceuticals (NASDAQ AERI) traded up $0.75 during trading hours on Tuesday, hitting $58.80. 191,505 shares of the stock traded hands, compared to its average volume of 344,264. Aerie Pharmaceuticals has a one year low of $37.80 and a one year high of $66.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24. The company has a market cap of $2,160.00, a price-to-earnings ratio of -17.55 and a beta of 1.11.

Institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its stake in Aerie Pharmaceuticals by 11.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after buying an additional 275 shares in the last quarter. Quantbot Technologies LP boosted its stake in Aerie Pharmaceuticals by 792.5% during the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after buying an additional 2,647 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Aerie Pharmaceuticals by 2,711.4% during the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after buying an additional 3,579 shares in the last quarter. Amalgamated Bank acquired a new stake in Aerie Pharmaceuticals during the second quarter worth $204,000. Finally, Great West Life Assurance Co. Can boosted its stake in Aerie Pharmaceuticals by 65.0% during the third quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after buying an additional 1,639 shares in the last quarter.

WARNING: “Mizuho Reiterates “Buy” Rating for Aerie Pharmaceuticals (NASDAQ:AERI)” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2018/01/11/aerie-pharmaceuticals-aeri-receives-buy-rating-from-mizuho.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply